Department of Neurology, Faculty Hospital Trenčín, Trencin, Slovakia.
Department of Neurology, Faculty of Medicine, P.J. Šafarik University and University Hospital L. Pasteur, Košice, Slovakia.
Womens Health (Lond). 2021 Jan-Dec;17:1745506521999495. doi: 10.1177/1745506521999495.
There is an ongoing debate about the use of recombinant tissue plasminogen activator in acute stroke during pregnancy. The aim of our case report is to present that even in a small stroke centre intravenous thrombolysis can be used on a pregnant woman if the benefit outweighs the risk and to summarize the diagnostic workup in a pregnant woman with stroke.
Our case describes a 31-year-old woman presenting in her third trimester with a sudden onset of slurred speech, severe right hemiparesis, facial nerve central palsy, eyes deviation to the left, right side hemianopia, hemisensory loss, psychomotor agitation and pain in the right lower limb. She was successfully treated with recombinant tissue plasminogen activator with almost complete recovery (NIHSS 1 after 10 days), and 23 days after intravenous thrombolysis, she delivered in the 37th week a healthy male infant. The first documented successful outcome from thrombolysis for this condition in Slovakia supports the notion of giving intravenous recombinant tissue plasminogen activator to pregnant patients with disabling ischaemic stroke who meet the criteria for thrombolysis.
At the end of case study, a recommended diagnostic workup for acute treatment of stroke in pregnant women is presented.
在怀孕期间急性卒中使用重组组织型纤溶酶原激活物一直存在争议。我们的病例报告旨在表明,如果获益超过风险,即使在小卒中中心也可以对孕妇使用静脉溶栓治疗,并总结孕妇卒中的诊断方法。
我们的病例描述了一位 31 岁女性,在妊娠晚期突然出现言语不清、严重右侧偏瘫、面神经中枢性麻痹、眼睛向左偏斜、右侧偏盲、半感觉缺失、精神运动激越和右下肢疼痛。她成功接受了重组组织型纤溶酶原激活物治疗,几乎完全恢复(10 天后 NIHSS 为 1),在静脉溶栓后 23 天,她在第 37 周分娩了一名健康男婴。这是斯洛伐克首例成功溶栓治疗该病症的病例,支持对符合溶栓标准的有残疾性缺血性卒中的孕妇给予静脉内重组组织型纤溶酶原激活物的观点。
在病例研究结束时,提出了用于孕妇急性卒中治疗的推荐诊断方法。